Fig. 6: GBM with high HER2-EGFR signaling tends to avoid high RNF8 expression as RNF8 overexpression impedes GBM tumorigenicity. | Cell Death & Differentiation

Fig. 6: GBM with high HER2-EGFR signaling tends to avoid high RNF8 expression as RNF8 overexpression impedes GBM tumorigenicity.

From: CAMK2D serves as a molecular scaffold for RNF8-MAD2 complex to induce mitotic checkpoint in glioma

Fig. 6

A Correlative analysis of RNF8 mRNA levels with glioma grades in two independent glioma patient cohorts. Wilcoxon-Mann-Whitney exact test. **P < 0.01. B, C Immunohistochemistry (IHC) scores of RNF8 in different grades of gliomas using glioma patient tissue microarray. C Representative images of the IHC scores of RNF8 in (B). D Correlative analysis of RNF8 mRNA levels with glioma patient survival in multiple glioma patient cohorts. OS: overall survival. Wald test. E Top 5 proteins that are upregulated in RNF8low vs RNF8high gliomas in the TCGA RPPA dataset using GlioVis (http://gliovis.bioinfo.cnio.es/). F RPPA analysis of HER2-pY1248 and EGFR-pY1173 in RNF8low versus RNF8high gliomas using TCGA cohort. ***P < 0.001, t-test. G, H In vivo bioluminescence-based imaging of post-orthotropic injection of TS543 overexpressing GFP or RNF8. H Representative images of the tumor-bearing NSG mice in (G) (n = 5) (mean±SD). *P < 0.05. I Kaplan Meier curves of mice implanted with GFP or RNF8 overexpressing TS543. Log rank test.

Back to article page